EO2401 is an off-the-shelf, microbiome-derived, multipeptide vaccine that combines peptides that mimic cancer-driver antigens (IL13Ra2, BIRC5, and FOXM1) and the helper peptide UCP2, which is currently being assessed in a Phase 1B/2A trial of patients with progressive GBM +/− ICI/bevacizumab therapy (ROSALIE, NCT04116658) [94,95]. This evidence concerns the gene BIRC5 and glioblastoma.